What are the main changes to the Amended and Restated 2009 Equity Incentive Plan?

The primary changes include an increase of 17,100,000 shares to the plan's authorized pool. Other material amendments involve how shares are counted (e.g., shares withheld for taxes on 'full value' awards and repurchases will be re-added to the pool), dividends/dividend equivalents on performance awards will only be paid if performance conditions are met, and the administrator gains discretion for automatic exercises of certain in-the-money stock options. Certain performance criteria for Section 162(m) compensation were also eliminated.

What was the outcome of the director elections?

All 13 nominees for the Board of Directors were elected to serve a one-year term. The vote tallies show a significant majority of 'Votes For' for each nominee, indicating strong shareholder support for the current board composition.

What does the approval of the equity incentive plan mean for potential share dilution?

The approval of the Amended and Restated 2009 Equity Incentive Plan allows for the issuance of an additional 17,100,000 shares. This increases the potential for future share dilution as these shares can be granted as stock options or other equity awards to employees and executives. Investors should monitor the company's future grant practices and their impact on earnings per share.

AMGN 8-K: Leadership Changes & Shareholder Matters

Q: Was the company's auditor ratified?

Yes, Ernst & Young LLP was ratified as Amgen's independent registered public accountants for the fiscal year ending December 31, 2013. The ratification received overwhelming support from shareholders.

Summary

Amgen Inc. (AMGN) filed an 8-K report on May 23, 2013, detailing the results of its Annual Meeting of Stockholders held on May 22, 2013. The key outcomes of the meeting include the approval of the Amended and Restated 2009 Equity Incentive Plan, which increases the authorized share pool and introduces several amendments to its terms. Additionally, all 13 director nominees were elected, and Ernst & Young LLP was ratified as the independent registered public accountants for the fiscal year ending December 31, 2013. Investors should note the approval of the Amended and Restated 2009 Equity Incentive Plan, as this impacts potential future equity awards and share dilution. The plan's amendments include changes to share counting for certain awards, dividend payments tied to vesting, potential automatic exercise of in-the-money stock options, and the elimination of certain performance criteria for Section 162(m) compensation. The overwhelming support for director elections and auditor ratification indicates continued confidence from shareholders in the company's governance and oversight.

Key Highlights

1Amgen's Annual Meeting of Stockholders on May 22, 2013, saw the approval of the Amended and Restated 2009 Equity Incentive Plan.
2The approved plan increases the share pool available for issuance by 17,100,000 shares, bringing the total to 104,280,107 shares.
3Key amendments to the equity plan include changes to share counting for withheld taxes on full value awards and repurchases, dividend payments contingent on performance vesting, and administrator discretion for automatic option exercises.
4All 13 director nominees were elected to serve a one-year term, indicating strong shareholder confidence in the board.
5Ernst & Young LLP was ratified as Amgen's independent registered public accountants for the fiscal year ending December 31, 2013.
6Shareholders approved the company's executive compensation in an advisory vote.
7The filing also confirms that no other matters were submitted for stockholder action at the meeting.

AMGEN INC 8-K Report, Executive Changes (May 23, 2013)

Summary

Key Highlights

Frequently Asked Questions